近期III期试验失败的教训：不要基于II期试验的回顾性亚组分析来设计III期试验。 - Suppr

Suppr

超能文献

Lessons from Recent Phase III Trial Failures: Don't Design Phase III Trials Based on Retrospective Subgroup Analyses from Phase II Trials.

作者信息

Rosenfeld Philip J, Feuer William J

机构信息

Miami, Florida.

出版信息

Ophthalmology. 2018 Oct;125(10):1488-1491. doi: 10.1016/j.ophtha.2018.06.002.

DOI:10.1016/j.ophtha.2018.06.002

PMID:30243330

Abstract

摘要

相似文献

Lessons from Recent Phase III Trial Failures: Don't Design Phase III Trials Based on Retrospective Subgroup Analyses from Phase II Trials.

Ophthalmology. 2018 Oct;125(10):1488-1491. doi: 10.1016/j.ophtha.2018.06.002.

Re: Rosenfeld et al.: Lessons from recent phase III trial failures: don't design phase III trials based on retrospective subgroup analyses from phase II trials (Ophthalmology. 2018;125:1488-1491).

Ophthalmology. 2019 Apr;126(4):e31-e32. doi: 10.1016/j.ophtha.2018.11.023.

Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.

Clin Ther. 2007 Sep;29(9):1850-61. doi: 10.1016/j.clinthera.2007.09.008.

Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials.

Ophthalmology. 2011 Mar;118(3):523-30. doi: 10.1016/j.ophtha.2010.07.011.

Technology evaluation: pegaptanib, Eyetech/Pfizer.

Curr Opin Mol Ther. 2003 Dec;5(6):673-9.

Re: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, et al.: Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials (Ophthalmology 2016;123:1751-1761).

Ophthalmology. 2017 Mar;124(3):e31-e32. doi: 10.1016/j.ophtha.2016.05.054.

Drugs in Phase II clinical trials for the treatment of age-related macular degeneration.

Expert Opin Investig Drugs. 2015 Feb;24(2):183-99. doi: 10.1517/13543784.2015.961601. Epub 2014 Sep 22.

[Correlation of indocyanine green angiography findings and expression of vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes].

Nippon Ganka Gakkai Zasshi. 2000 Jun;104(6):390-5.

Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases.

Am J Ophthalmol. 2006 Oct;142(4):660-8. doi: 10.1016/j.ajo.2006.05.061.

Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results.

Ophthalmology. 2003 May;110(5):979-86. doi: 10.1016/S0161-6420(03)00085-X.

引用本文的文献

Challenges and opportunities of developing small-molecule therapies for age-related macular degeneration.

Arch Pharm Res. 2024 Jun;47(6):538-557. doi: 10.1007/s12272-024-01503-3. Epub 2024 Jun 20.

Rethinking the potential and necessity of drug delivery systems in neovascular age-related macular degeneration therapy.

Front Bioeng Biotechnol. 2023 May 23;11:1199922. doi: 10.3389/fbioe.2023.1199922. eCollection 2023.

METTL3-mediated m6A modification of HMGA2 mRNA promotes subretinal fibrosis and epithelial-mesenchymal transition.

J Mol Cell Biol. 2023 Aug 3;15(3). doi: 10.1093/jmcb/mjad005.

From Marine Metabolites to the Drugs of the Future: Squalamine, Trodusquemine, Their Steroid and Triterpene Analogues.

Int J Mol Sci. 2022 Jan 19;23(3):1075. doi: 10.3390/ijms23031075.

PDGF Receptor Alpha Signaling Is Key for Müller Cell Homeostasis Functions.

Int J Mol Sci. 2021 Jan 25;22(3):1174. doi: 10.3390/ijms22031174.

Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities.

Prog Retin Eye Res. 2021 May;82:100906. doi: 10.1016/j.preteyeres.2020.100906. Epub 2020 Oct 3.

Implantable anti-angiogenic scaffolds for treatment of neovascular ocular pathologies.

Drug Deliv Transl Res. 2020 Oct;10(5):1191-1202. doi: 10.1007/s13346-020-00753-0.

Revisiting Therapies for Atopic Dermatitis that Failed Clinical Trials.

Clin Drug Investig. 2020 May;40(5):421-431. doi: 10.1007/s40261-020-00905-7.

Choroidal Neovascularization: Mechanisms of Endothelial Dysfunction.

Front Pharmacol. 2019 Nov 29;10:1363. doi: 10.3389/fphar.2019.01363. eCollection 2019.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验